Effect of Early Use of Levosimendan Versus Placebo on Top of a Conventional Strategy of Inotrope Use on a Combined Morbidity-mortality Endpoint in Patients With Cardiogenic Shock

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 610 participants.

Also called NCT04020263

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 610 participants (planned count) (from the registry)
Sponsor
Pr Bruno LEVY (from the registry)
Registry
  • NCT NCT04020263
  • EU CT 2024-513811-29-00
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
France (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT04020263. Randomized; triple masking; primary purpose treatment. Start 2023-07-03 (actual); primary completion 2027-02-03 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of Early Use of Levosimendan Versus Placebo on Top of a Conventional Strategy of Inotrope Use on a Combined Morbidity-mortality Endpoint in Patients With Cardiogenic Shock
Acronym
LevoHeartShock
Condition
Cardiogenic Shock
Intervention (Drug)
Levosimendan 2.5 MG/ML Injectable Solution
Intervention (Drug)
Placebo
Lead sponsor
Pr Bruno LEVY (class: other)

Record details

Record id
cardio:ct-nct04020263
Content hash
616324abb24b2538721236185ca1fa691f1467a16096c0b8c3070056d24a9c5b